Episode Details
Back to Episodes
Siren's $30M Erasca Bet Signals RAS Cancer Hope
Description
New York hedge fund Siren has invested heavily in Erasca, a biotech company targeting tough cancers. Siren bought 2.5 million shares, valued at $182 million, making it their third-largest holding. Erascas lead candidate, ERAS-0015, showed promising early results in lung and pancreatic cancer trials. With $409 million in cash, Erasca is poised for late 2028 development, and Sirens investment indicates confidence in the companys potential.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/221a65b9f4b180dd